DNA-protein Crosslink Proteases in Genome Stability

Overview

Journal Commun Biol

Specialty Biology

Date 2021 Jan 5

PMID 33398053

Citations 37

Authors

Annamaria Ruggiano

Kristijan Ramadan

Affiliations

Soon will be listed here.

Abstract

Proteins covalently attached to DNA, also known as DNA-protein crosslinks (DPCs), are common and bulky DNA lesions that interfere with DNA replication, repair, transcription and recombination. Research in the past several years indicates that cells possess dedicated enzymes, known as DPC proteases, which digest the protein component of a DPC. Interestingly, DPC proteases also play a role in proteolysis beside DPC repair, such as in degrading excess histones during DNA replication or controlling DNA replication checkpoints. Here, we discuss the importance of DPC proteases in DNA replication, genome stability and their direct link to human diseases and cancer therapy.

Citing Articles

Elevated reactive oxygen species can drive the alternative lengthening of telomeres pathway in ATRX-null cancers.

Goncalves T, Cunniffe S, Ma T, Mattis N, Rose A, Kent T Nucleic Acids Res. 2025; 53(4).

PMID: 39921567 PMC: 11806356. DOI: 10.1093/nar/gkaf061.

Flap endonuclease 1 repairs DNA-protein cross-links via ADP-ribosylation-dependent mechanisms.

Sun Y, Jenkins L, El Touny L, Zhu L, Yang X, Jo U Sci Adv. 2025; 11(2):eads2919.

PMID: 39792662 PMC: 11721697. DOI: 10.1126/sciadv.ads2919.

Understanding DNA replication and replication stress as avenues to combat cancer.

Naim V Commun Biol. 2024; 7(1):1578.

PMID: 39592851 PMC: 11599382. DOI: 10.1038/s42003-024-07250-x.

Homozygous synonymous FAM111A variant underlies an autosomal recessive form of Kenny-Caffey syndrome.

Bonde L, Abdelrazek I, Seif L, Alawi M, Matrawy K, Nabil K J Hum Genet. 2024; 70(2):87-97.

PMID: 39501122 PMC: 11762410. DOI: 10.1038/s10038-024-01301-1.

Causes and consequences of DNA double-stranded breaks in cardiovascular disease.

Marian A Mol Cell Biochem. 2024; .

PMID: 39404936 DOI: 10.1007/s11010-024-05131-9.

References

Verma R, Oania R, Fang R, Smith G, Deshaies R . Cdc48/p97 mediates UV-dependent turnover of RNA Pol II. Mol Cell. 2011; 41(1):82-92. PMC: 3063307. DOI: 10.1016/j.molcel.2010.12.017. View

Nakano T, Katafuchi A, Matsubara M, Terato H, Tsuboi T, Masuda T . Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells. J Biol Chem. 2009; 284(40):27065-76. PMC: 2785636. DOI: 10.1074/jbc.M109.019174. View

Reinking H, Hofmann K, Stingele J . Function and evolution of the DNA-protein crosslink proteases Wss1 and SPRTN. DNA Repair (Amst). 2020; 88:102822. DOI: 10.1016/j.dnarep.2020.102822. View

Maskey R, Flatten K, Sieben C, Peterson K, Baker D, Nam H . Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis. Nucleic Acids Res. 2017; 45(8):4564-4576. PMC: 5416836. DOI: 10.1093/nar/gkx107. View

Hoffmann S, Pentakota S, Mund A, Haahr P, Coscia F, Gallo M . FAM111 protease activity undermines cellular fitness and is amplified by gain-of-function mutations in human disease. EMBO Rep. 2020; 21(10):e50662. PMC: 7534640. DOI: 10.15252/embr.202050662. View

Tang X, Cao J, Zhang L, Huang Y, Zhang Q, Rong Y . Maternal Haploid, a Metalloprotease Enriched at the Largest Satellite Repeat and Essential for Genome Integrity in Embryos. Genetics. 2017; 206(4):1829-1839. PMC: 5560791. DOI: 10.1534/genetics.117.200949. View

Rios-Szwed D, Alvarez V, Sanchez-Pulido L, Garcia-Wilson E, Jiang H, Bandau S . FAM111A regulates replication origin activation and cell fitness. Life Sci Alliance. 2023; 6(12). PMC: 10551639. DOI: 10.26508/lsa.202302111. View

Reinking H, Kang H, Gotz M, Li H, Kieser A, Zhao S . DNA Structure-Specific Cleavage of DNA-Protein Crosslinks by the SPRTN Protease. Mol Cell. 2020; 80(1):102-113.e6. PMC: 7534798. DOI: 10.1016/j.molcel.2020.08.003. View

Mao Y, Desai S, Ting C, Hwang J, Liu L . 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem. 2001; 276(44):40652-8. DOI: 10.1074/jbc.M104009200. View

10.

Bruhn C, Foiani M . A model of DNA damage response activation at stalled replication forks by SPRTN. Nat Commun. 2019; 10(1):5671. PMC: 6908633. DOI: 10.1038/s41467-019-13610-7. View

11.

Elsasser S, Gali R, Schwickart M, Larsen C, Leggett D, Muller B . Proteasome subunit Rpn1 binds ubiquitin-like protein domains. Nat Cell Biol. 2002; 4(9):725-30. DOI: 10.1038/ncb845. View

12.

Yip M, Bodnar N, Rapoport T . Ddi1 is a ubiquitin-dependent protease. Proc Natl Acad Sci U S A. 2020; 117(14):7776-7781. PMC: 7149228. DOI: 10.1073/pnas.1902298117. View

13.

Fielden J, Wiseman K, Torrecilla I, Li S, Hume S, Chiang S . TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts. Nat Commun. 2020; 11(1):1274. PMC: 7062751. DOI: 10.1038/s41467-020-15000-w. View

14.

Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, Pedersen R . 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol. 2011; 13(3):243-53. DOI: 10.1038/ncb2201. View

15.

Interthal H, Chen H, Champoux J . Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J Biol Chem. 2005; 280(43):36518-28. PMC: 1351008. DOI: 10.1074/jbc.M508898200. View

16.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

17.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

18.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Murai J, Huang S, Renaud A, Zhang Y, Ji J, Takeda S . Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2013; 13(2):433-43. PMC: 3946062. DOI: 10.1158/1535-7163.MCT-13-0803. View